MissionIRNewsBreaks – Sigma Labs Inc. (NASDAQ: SGLB) Transforming the Blossoming 3D-Printing Sector with Groundbreaking Quality-Assurance Software

Sigma Labs (NASDAQ: SGLB), a developer of quality-assurance software for the commercial 3D-printing industry, has developed a method of overcoming quality-assurance obstacles that thwart 3D-metal printing from becoming fully integrated into modern manufacturing lines. An article discussing the company reads, “The company is about to revolutionize commercial 3D-printing metal by enabling nondestructive quality assurance during the production process. Sigma Labs’ proprietary PrintRite3D software is a real-time, computer-aided inspection (‘CAI’) technology long sought by 3D-printing companies to lower costs and increase yields. PrintRite3D(R) represents a breakthrough in the 3D-quality inspection sphere because it is the only known real-time, in-process, quality-assurance software for the commercial 3D-metal-printing industry. . . . 3D printing, also called additive manufacturing, is a technology that allows producers to transform a 3D-digital model of an object into a physical one by adding material rather than subtracting it, hence the additive in the name. The resulting 3D objects are made in a digitally controlled and operated process by depositing minuscule layers of material onto a substrate layer.”

To view the full article, visit http://ibn.fm/djUUY

About Sigma Labs Inc.

Sigma Labs (NASDAQ: SGLB) is a leading provider of quality-assurance software to the commercial, 3D-printing industry under the PrintRite3D(R) brand. Founded in 2010, Sigma is a software company that specializes in the development and commercialization of real-time, computer-aided inspection (CAI) solutions known as PrintRite3D for 3D advanced-manufacturing technologies. Sigma Labs’ advanced, computer-aided, software product revolutionizes commercial additive manufacturing, enabling nondestructive quality assurance mid-production and uniquely allowing errors to be corrected in real time. For more information, visit the company’s website at www.SigmaLabsInc.com.

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Building AI-driven Ovarian Cancer Model to Predict Tumor Drug Response, Patient Outcome

Predictive Oncology (NASDAQ: POAI), through its subsidiary Helomics, is sequencing ovarian cancers as part of a CancerQuest 2020 project, building the largest ovarian multi-omic database in the world. An article discussing the company reads, “As part of its CancerQuest 2020 project, Predictive Oncology, through Helomics, recently signed a collaborative agreement with UPMC-Magee to establish a data- and artificial-intelligence-driven approach to treating ovarian cancer. Based on the agreement, the partnership is designed to validate the significant value of using AI-powered decision-making for identifying specific treatments on specific genotypes to predict clinical outcomes for ovarian cancer patients. . . . Helomics has also begun sequencing retrospective ovarian cancer cases from the UPMC-Magee collaboration (http://ibn.fm/I4Lnb). As part of the sequencing process, Helomics is analyzing the mutations in the tumor (genome) and the expression of genes (transcriptome) in order to build a comprehensive multi-omic picture of the tumor. That information can then be brought together with Helomics’ data set of drug-response profiles to build an AI-driven predictive model of ovarian cancer.”

To view the full article, visit http://ibn.fm/Ggbmd

About Predictive Oncology Inc.

Predictive Oncology (NASDAQ: POAI) operates through five segments (domestic, international, clinical, CRO and DCHIP), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient-treatment decisions by providing an evidence-based road map for therapy. In addition to its proprietary, precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered, proprietary bioinformatics platform (D-CHIP) to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms, which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient-specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Sigma Labs Inc. (NASDAQ: SGLB) Demonstrates Latest PrintRite3D(R) Version at Major Global 3D-Printing Conference

Developer of quality-assurance software for the commercial 3D-printing industry Sigma Labs Inc. (NASDAQ: SGLB) recently demonstrated the latest version of its proprietary technology PrintRite3D(R) in collaboration with Materialise NV at the Formnext 2019 conference held in Frankfurt, Germany. A recent article discussing the company reads, “At the event, Sigma Labs’ chief technology officer Darren Beckett presented on ‘The Integration of PrintRite3D Melt Pool Monitoring Software with Materialise’s Machine Control Platform (MCP) for Advanced Process Control.’ The presentation showcased version 5.2 of the software, which features several software enhancements including the automated anomaly detection with Z connectivity that identifies thermal defects, which propagate across multiple layers and enhanced data-trend analysis and customizable thresholding that enable automatic alerts. These new functionalities should further strengthen the capabilities of additive manufacturing for serial production.”

To view the full article, visit http://ibn.fm/Z3Ulv

About Sigma Labs Inc.

Sigma Labs (NASDAQ: SGLB) is a leading provider of quality-assurance software to the commercial 3D-printing industry under the PrintRite3D(R) brand. Founded in 2010, Sigma is a software company that specializes in the development and commercialization of real-time, computer-aided inspection (CAI) solutions known as PrintRite3D for 3D advanced manufacturing technologies. Sigma Labs’ advanced, computer-aided, software product revolutionizes commercial additive manufacturing, enabling nondestructive quality assurance mid-production, uniquely allowing errors to be corrected in real time. For more information, visit the company’s website at www.SigmaLabsInc.com.

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – SRAX, Inc. (NASDAQ: SRAX) Extends Expiration Time for BIGtoken Special Dividend through December 31, 2020

SRAX (NASDAQ: SRAX), a digital marketing and consumer data management technology company, today announced that it has extended the expiration time for its special dividend right from December 31, 2019 to on or before 5:00 PM ET on December 31, 2020. Per the update, on September 17, 2018, the company issued a non-transferable right (“Dividend Right”) to receive, at no charge, a special dividend to holders of the company’s Class A common stock as well as certain holders of the company’s common stock equivalents. The Special Dividend, if and when declared, will consist of such number and designation of the SRAX subsidiary BIGtoken, Inc.’s securities (“Special Dividend”) as determined at the sole discretion of the company’s management. The Dividend Right was set to expire on or before 5:00 PM ET on December 31, 2019 (the “Expiration Time”), unless extended by the company. The Dividend Right will now expire if the Special Dividend is not declared on or before 5:00 PM ET on December 31, 2020, unless further extended by SRAX.

To view the full press release, visit http://ibn.fm/G8vKA

About SRAX Inc.

SRAX is a digital-marketing and consumer-data-management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and the characteristics of those consumers across marketing channels. Monetizing its data sets, SRAX is growing multiple, recurring revenue streams through its various platforms. Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby offering everyone in the internet ecosystem choice, transparency and compensation. SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor-relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform. For more information, visit the company’s website at www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary’s Revolutionary Technology Enables Faster, More Accurate Tumor Identification

Data and artificial-intelligence (“AI”) driven, discovery-services company Predictive Oncology’s (NASDAQ: POAI) subsidiary TumorGenesis is developing quicker, less costly and more precise Patient Derived Xenograft (“PDx”) cancer models that better mimic the patient’s tumor. An article discussing the company reads, “TumorGenesis excels not only in identifying cancer cell lines but also in developing a medium necessary to grow cancer-cell colonies in a way that will not compromise their integrity — a consideration critical to the success of every cancer research. This revolutionary technology is creating an unparalleled competitive advantage for the parent company POAI, as it allows for faster and more accurate identification of tumors and the development of patient-specific treatment options. The company expects this revolutionary product to hit the market by the end of the year. . . . What is unique with TumorGenesis’ state-of-the-art approach to cancer research is that the company has already developed 25 validated, ovarian, cancer-cell types that mature into uncompromised tumor colonies not only in vitro but in rats and mice too — a formidable accomplishment as 15 out of 25 cell lines represent around 90% of all ovarian cancers discovered so far, including those most virulent and deadly.”

To view the full article, visit http://ibn.fm/sS0ol

About Predictive Oncology Inc.

Predictive Oncology (NASDAQ: POAI) operates through five segments (domestic, international, clinical, CRO and DCHIP), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient-treatment decisions by providing an evidence-based road map for therapy. In addition to its proprietary, precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered, proprietary bioinformatics platform (D- CHIP) to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms, which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient-specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – SRAX Inc. (NASDAQ: SRAX) Favorably Positioned for Growth in Q4

SRAX (NASDAQ: SRAX), a digital-marketing and consumer-data-management technology company, recently hosted a conference call for executives to share third-quarter earnings and outlook for Q4 with investors (http://ibn.fm/j8ME2). An article discussing the company reads, “Additional verticals allow SRAX to sell access to specific data sets to an increasing number of brands. The two platforms are being leveraged to build crossover into the verticals. ‘We spent the past few quarters integrating our platforms and realigning the sales process and are now well positioned for growth,’ added SRAX CEO Christopher Miglino. ‘Looking ahead, we expect to accelerate revenue by engaging with big brands across all three of our platforms.’”

To view the full article, visit http://ibn.fm/27vR4

About SRAX Inc.

SRAX is a digital-marketing and consumer-data-management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and the characteristics of those consumers across marketing channels. Monetizing its data sets, SRAX is growing multiple, recurring revenue streams through its various platforms. Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby offering everyone in the internet ecosystem choice, transparency and compensation. SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor-relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform. For more information, visit the company’s website at www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Jerrick Media Holdings, Inc. (JMDA) CEO Provides Weekly Company Recap Including Company Updates, Insights

Jerrick Media Holdings (OTCQB: JMDA), a holding company that gives technology products the resources and opportunities to make ideas a reality, recently highlighted the most significant news, updates and insights from Jerrick, Vocal and throughout the industry. In an article authored by JMDA CEO & founder Jeremey Frommer on Vocal.Media titled ‘Jerrick CEO’s Week in Review: 12/16/19 – 12/20/19’, Frommer discusses his executive priorities and his insights regarding company revenues. “In addition to the continued growth of deferred revenues from the Vocal+ subscription model, the company has visibility on its expanding revenue pipeline for 2020. As CEO, this marks the first material quarterly guidance that I have been able to communicate in advance and meet in expectation. It sets the baseline for measuring future exponential growth on a quarter over quarter basis without materially increasing operating expenses. Jerrick and its shareholders will soon have an even clearer and unobstructed line of sight to cash flow breakeven,” Jerrick Media Holdings CEO & founder Jeremey Frommer stated in the news release.

To view the full article, visit http://ibn.fm/FEWkO

About Jerrick

Jerrick is a holding company that develops technology-based solutions. Its flagship product Vocal is a long-form, digital publishing platform focused on supporting content creators by providing them with publishing tools and monetization features that are embedded within digital communities. Vocal is architected to enable targeted marketing of branded content and e-commerce opportunities embedded within long-form content. Vocal’s community sites are managed by a dedicated team, whose primary focus is on creating safe communities and identifying monetization opportunities within them. For more information, visit the company’s website at https://jerrick.media.

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI) Ships First Wave of Vaporizer Offerings

Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (the “Company” or “Organigram”), a leading licensed producer of cannabis, today announced release of the first of its ‘Cannabis 2.0’ products, including Trailblazer Spark, Flicker and Glow 510-thread Torch vape cartridges.  According to the update, shipments of the custom-designed cartridges were sent to Manitoba, Saskatchewan, Ontario, New Brunswick and Nova Scotia, starting December 17, from the Company’s Moncton production campus. “As a company, bringing the next-generation of cannabis products to market without delay was important to us. We are proud to support access to tested, quality derivative-based products that we expect to help strengthen the regulated market and benefit those who prefer those product types over others,” Organigram CEO Greg Engel said in the news release. “Being one of the first licensed producers in the country ready to provide vape products, following the expiration of Health Canada’s 60-day notification period, illustrates that degree of focus and commitment. It speaks to an extraordinary effort by our internal teams who helped bring the Trailblazer Torch to market.”

To view the full press release, visit http://ibn.fm/II5tn

About Organigram Holdings Inc.

Organigram Holdings Inc. is a NASDAQ Global Select and TSX listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of cannabis and cannabis-derived products in Canada. Organigram is focused on producing high-quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to extend the Company’s global footprint. Organigram has also developed a portfolio of legal adult use recreational cannabis brands including The Edison Cannabis Company, Ankr Organics and Trailblazer. Organigram’s primary facility is located in Moncton, New Brunswick and the Company is regulated by the Cannabis Act and the Cannabis Regulations (Canada).  For more information, visit the company’s website at www.Organigram.ca.

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Drug-Delivery Platform Continues Reaching New Milestones

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, recently announced further advances in its proprietary, oral, drug-delivery platform: DehydraTECH(TM). An article discussing the company reads, “Lexaria’s early pilot-stage human trials with tetrahydrocannabinol (THC) delivery show its newest formulation of DehydraTECH-enhanced edibles begin providing cannabinoid effectiveness in less than 10 minutes, which is about twice as fast as traditional DehydraTECH and four to six times faster than generic industry formulations, according to a company news release (http://ibn.fm/mwAS9). . . . Lexaria has been developing DehydraTECH solutions as alternatives to smoked or vaped drug delivery over the course of the past three years, establishing a means whereby edible consumption of certain substances can provide results at rates comparable to inhaled substances and faster than ingested substances in general.”

To view the full article, visit http://ibn.fm/ys4jC

About Lexaria Bioscience Corp.

Lexaria Bioscience is a global innovator in drug-delivery platforms. The company’s patented DehydraTECH drug-delivery technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time of onset and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products, as well as to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Youngevity International Inc. (NASDAQ: YGYI) Announces Payment Timing of Regular Monthly Dividend for Series “D” Cumulative Redeemable Perpetual Preferred Stock

Youngevity International (NASDAQ: YGYI), a leading multi-channel lifestyle company, today announced the timing for the payment of its declared regular monthly dividend of $0.203125 per share of its 9.75% Series D Cumulative Redeemable Perpetual Preferred Stock (NASDAQ: YGYIP) for December 2019. According to the update, the dividend will be payable on January 15, 2020 to holders of record as of December 31, 2019. The dividend will be paid in cash.

To view the full press release, visit http://ibn.fm/8YGgI

About Youngevity International, Inc.

Youngevity International, Inc. (NASDAQ: YGYI, YGYIP), is a multi-channel lifestyle company operating in three distinct business segments including a commercial coffee enterprise, a commercial hemp enterprise, and a multi-vertical omni direct selling enterprise. The company features a multi country selling network and has assembled a virtual Main Street of products and services under one corporate entity. YGYI offers products from the six top selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry, as well as innovative services. For investor information, please visit www.YGYI.com.

NOTE TO INVESTORS: The latest news and updates relating to YGYI are available in the company’s newsroom at http://ibn.fm/YGYI

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

SRAX Inc. (NASDAQ: SRAX) Focusing on Privacy, Data Ownership as It Builds Valuable Opt-In Consumer Data Set

• SRAX offers consumers ability to receive payment for release of their data
• Company’s emphasis is on protection of individuals’ personal information, a critical element in today’s data world
• SRAX’s BIGtoken platform provides advertisers access to verified consumer data

SRAX Inc. (NASDAQ: SRAX) is a digital marketing and data management technology company providing marketers and consumers tools to unlock the value of data. Privacy and data ownership are the Company’s emphasis. Headquartered in Los Angeles, SRAX focuses on offering consumers the ability to own their data and receive payment for the release of it. SRAX is in the process of building the most valuable opted-in consumer data set in the world.

The protection of individuals’ personal information is a major issue today. Recently, the Consumer Online Privacy Rights Act (COPRA) was officially introduced in the U.S. Senate. The strict proposal would give U.S. citizens the same privacy rights that citizens of the European Union have under the General Data Protection Regulation (GDPR) and has serious implications for United States companies.

“With COPRA in place, consumers would have the right to request which data companies are collecting and ask for that data to be deleted or corrected,” noted an article written by the BIGtoken team (http://ibn.fm/27yOb). “Companies would also need to get explicit consent from anyone before collecting and sharing their data.”

SRAX is at the vanguard of developing a consumer-managed data marketplace and giving consumers control over their information – a power previously unavailable to consumers. The SRAX BIGtoken platform allows consumers to own and monetize their data. This control is significant because today’s consumers expect to receive compensation for releasing their data, while at the same time keeping that data safe, secure and private.

BIGtoken essentially enables consumers to control which pieces of their own data are for sale and which companies can buy them. In addition, BIGtoken provides advertisers access to verified consumer data to better reach and serve audiences. With privacy issues and concerns regarding social media channels such as Facebook, Twitter, Snapchat, LinkedIn and others on everyone’s radar, SRAX offers a premier solution via BIGtoken as the platform creates a secure and transparent environment for consumers. The opportunity to earn money from the release of data has resulted in BIGtoken racking up more than 16 million users around the world thus far, with that number growing every day.

Once consumers grant BIGtoken access to their information, a cooperative relationship is established between SRAX and its customers. Consumers who sell access to their digital data receive compensation with points that they can redeem for cash or gift cards. At the same time, BIGtoken is able to provide verified, high-quality data to advertisers that pay a premium to access consumer-corroborated information for their campaigns. SRAX does not sell BIGtoken data directly to advertisers; it sells access to the data, in the form of anonymized segments.

Along with BIGtoken, SRAX’s product family includes SRAX IR, SRAX Shopper, SRAX Core and SRAX Lux. SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. SRAX Shopper delivers a cross-channel, premium digital experience at scale to high-value shopper audiences. SRAX Core offers one complete dashboard to manage digital media campaigns, inventory and reporting. SRAX Lux targets and reaches luxury consumers at luxury retail stores and high-end art galleries, as well as music, film, fashion and sports events.

SRAX is committed to its mission of delivering tools to unlock the value of data, benefitting consumers and advertisers alike. Significant for investors is that through monetizing its data sets, SRAX is growing numerous, recurring revenue streams by way of its different platforms. SRAX is offering everyone in the internet ecosystem choice, transparency and compensation – coupled with a commitment to privacy and data ownership.

For more information, visit the company’s website at www.SRAX.com

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html